Eli Lilly said Thursday that retatrutide, its experimental triple-hormone obesity drug, succeeded in two more late-stage trials, giving the company what it says is a complete data package for regulatory filings starting in early 2027.
The weight-loss results are the headline, and they are substantial. The cardiovascular results, which arrived in the same release, are more complicated — and they are the reason the reaction among analysts has been more measured than the topline suggests.
The weight numbers
TRIUMPH-2 enrolled 1,152 adults with type 2 diabetes and obesity or overweight, a group that typically loses less weight on these drugs than people without diabetes. Over 80 weeks, participants lost an average of 12.7% of body weight on 4 mg, 19.1% on 9 mg and 20.8% on 12 mg, against 4.0% on placebo. A1C fell by as much as 1.6 percentage points from a 7.7% baseline, compared with 0.2 on placebo.
TRIUMPH-3 enrolled 1,949 adults with severe obesity — a BMI of 35 or higher — and established cardiovascular disease. Participants lost 21.6% on 9 mg and 22.6% on 12 mg, versus 3.2% on placebo.
One caveat applies to all of those figures. They are what Lilly calls efficacy estimand results, meaning they describe what would have happened if every participant had stayed on the drug for the full 80 weeks without starting other weight-management treatment. That is a legitimate and standard way to report a trial, but it is not the same as the average result across everyone who was randomized, and it tends to produce larger numbers than the alternative.
The heart data is the open question
TRIUMPH-3 recruited people who already had cardiovascular disease, so it included pre-specified analyses of major adverse cardiac events. Those numbers did not come out cleanly.
On the five-part endpoint — death from any cause, heart attack, stroke, heart failure event or coronary revascularization — there were 44 events among participants on retatrutide and 52 on placebo, a hazard ratio of 0.82. But the confidence interval runs from 0.55 to 1.22, which means the data are compatible with a meaningful benefit and also with no benefit at all.
On the narrower three-part endpoint of cardiovascular death, heart attack or stroke, there were 27 events on retatrutide and 23 on placebo — a hazard ratio of 1.12, pointing the wrong way, with an interval from 0.64 to 1.96 that is too wide to conclude anything from.
Lilly noted that cardiac events happened less often than expected in both arms, which is the mechanical explanation: with few events, the estimates are imprecise. The company also reported a non-pre-specified on-treatment analysis with more favorable ratios, 0.73 and 0.92, though analyses chosen after the fact carry less weight.
The fair reading is that TRIUMPH-3 was a weight-loss trial in a cardiovascular population, not a cardiovascular outcomes trial. It was not powered to detect an effect on heart attacks and strokes, and it did not. A dedicated outcomes trial is what would settle the question.
Retatrutide did move cardiovascular risk factors substantially at the top dose: triglycerides down 37.0%, non-HDL cholesterol down 16.5%, systolic blood pressure down 9.3 mmHg, waist circumference down 19 cm and high-sensitivity CRP down 51.2%. Whether that translates into fewer cardiac events is precisely what the trial could not show.
Side effects and dropouts
The adverse events were mostly what this drug class produces: diarrhea in up to a third of participants, along with nausea, constipation, decreased appetite and vomiting, generally mild to moderate and mostly resolving during treatment.
Two things stand out. Dysesthesia — altered or unpleasant sensation, such as tingling or burning — occurred more often on retatrutide than placebo in both trials, reaching 7.3% at the top dose in TRIUMPH-2 against 0.7% on placebo. And discontinuation due to adverse events was meaningfully higher than placebo: up to 11.6% in TRIUMPH-2 and 13.5% in TRIUMPH-3, versus roughly 5% on placebo in both.
What happens next
"Across five positive Phase 3 studies, retatrutide has shown powerful efficacy," said Kenneth Custer, president of Lilly Cardiometabolic Health, adding that the company now has the data to support submissions for obesity, knee osteoarthritis pain and obstructive sleep apnea.
Lilly is finishing the manufacturing documentation required for a Biologics License Application and plans to file with the FDA in the first quarter of 2027. Full results will be presented at medical meetings and published in peer-reviewed journals, which is when independent researchers will get to examine the cardiovascular analyses rather than a press release summary of them.
Until then, retatrutide remains investigational. It is not approved anywhere, it cannot legally be sold for human use, and material sold online under its name is not the studied product. Anyone weighing treatment for obesity or type 2 diabetes should be having that conversation with a clinician about the options that actually exist today.
